Christopher L. Jordan
General Counsel bij CHIMERIX, INC.
Profiel
Christopher L.
Jordan is currently the Vice President-Regulatory Affairs at Chimerix, Inc. He previously worked as the Senior Global Program Regulatory Director at Novartis AG, Vice President-Regulatory Affairs at Endocyte, Inc., and Principal at Eli Lilly & Co. He holds a graduate degree from George Washington University and an undergraduate degree from Purdue University.
Actieve functies van Christopher L. Jordan
| Bedrijven | Functie | Begin |
|---|---|---|
| CHIMERIX, INC. | General Counsel | 08-08-2022 |
Eerdere bekende functies van Christopher L. Jordan
| Bedrijven | Functie | Einde |
|---|---|---|
| ENDOCYTE, INC. | General Counsel | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| NOVARTIS AG | General Counsel | - |
Opleiding van Christopher L. Jordan
| George Washington University | Graduate Degree |
| Purdue University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CHIMERIX, INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Endocyte, Inc.
 Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
